All companies
Visit website
MedVector
OperatingMedVector Corp
Biotech · Founded 2017
Transforming Clinical Trials
Valuation cap ⓘ
$25.0M
As of Oct 2024 · from MedVectorConvertible Note 2 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$988,913
Across 2 rounds since 2020
Latest share price
$1.45
MedVector - Telemedicine for Clinical Trials Stock 1 offering price
Financials
FY2018–FY2024 · from SEC filings · hover any figure for its source$0
−$312K
2018
$0
−$512K
2019
$0
−$322K
2020
$0
−$687K
2021
$0
−$654K
2022
$0
−$705K
2023
$0
−$432K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
$0
Net income
-$311,702
-$512,456
-$322,214
-$687,288
-$653,737
-$704,633
-$431,991
Taxes paid
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$148,600
$26,998
$170,947
$369,811
$424,287
$64,386
$19,836
Accounts receivable
$0
$0
$21,028
$0
$0
$0
$0
Total assets
$188,600
$253,690
$458,668
$718,903
$759,063
$411,528
$376,022
Short-term debt
$500,302
$208,552
$312,959
$26,243
$360,140
$392,239
$639,320
Long-term debt
$0
$0
$0
$425,000
$1,085,000
$0
$0
Total liabilities
$500,302
$208,552
$312,959
$451,243
$1,445,140
$392,239
$639,320
Other
Headcount
—
2
2
0
0
2
0
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$10.9M
post-money
$25.0M
Valuation cap
MedVector - Telemedicine for Clinical Trials Stock 1
MedVectorConvertible Note 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $114.6K / $618KInvestors 60Valuation cap $25M
Raised $874.3K / $1.1MInvestors 555Post-money $10.9M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 5 of 6 annual reports (FY2020–FY2025)
555 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 18 filings on EDGARSource: ManualCIK 0001820902Share price $1.45
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.